Quick Answer
Galera Therapeutics, Inc. reported Net Income of $149.05 million for fiscal year 2025.
Galera Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | $149.05M +886.2% |
-$18.96M +67.9% |
-$59.08M +5.0% |
-$62.22M +22.7% |
-$80.53M -8.5% |
-$74.22M -42.9% |
| Diluted EPS | $0.64 +288.2% |
-$0.34 +74.4% |
-$1.33 | — | — | — |
| Total Assets | $7.20M -28.8% |
$10.10M -61.4% |
$26.14M -40.6% |
$44.04M -47.1% |
$83.31M -0.9% |
$84.10M -31.8% |
| Cash and Equivalents | $6.38M -23.1% |
$8.29M -54.6% |
$18.26M +328.0% |
$4.27M -78.5% |
$19.86M +25.1% |
$15.87M -13.5% |
| Stockholders Equity | $3.97M +102.7% |
-$148.04M -12.8% |
-$131.19M -20.2% |
-$109.18M -88.2% |
-$58.00M -1048.1% |
$6.12M -91.2% |
| R&D Expense | $349.0K -88.9% |
$3.15M -86.9% |
$24.11M -22.2% |
$31.01M -40.8% |
$52.42M -4.4% |
$54.84M +29.6% |
| Operating Income | -$2.54M +87.4% |
-$20.16M +59.1% |
-$49.26M +3.8% |
-$51.23M +30.2% |
-$73.37M -4.0% |
-$70.55M -39.2% |
| Shares Outstanding | 75.46M +0.0% |
75.46M +38.7% |
54.39M +90.8% |
28.51M +7.8% |
26.46M +5.9% |
24.98M +0.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$1.39M | +75.1% | -29.1% |
| Diluted EPS | September 30, 2025 | -$0.01 | +90.0% | — |
| Total Assets | September 30, 2025 | $5.00M | -43.8% | -17.3% |
| Cash and Equivalents | September 30, 2025 | $4.47M | -47.1% | -14.5% |
| Stockholders Equity | September 30, 2025 | -$149.22M | -4.3% | -0.9% |
| R&D Expense | September 30, 2025 | $130.0K | -57.4% | +54.8% |
| Operating Income | September 30, 2025 | -$1.44M | +75.7% | -26.5% |
| Shares Outstanding | September 30, 2025 | 75.46M | +38.7% | +0.0% |
- Galera Therapeutics, Inc. reported Net Income of $149.05 million for fiscal year 2025.
- Galera Therapeutics, Inc. showed an increase of +886.2% in Net Income compared to the prior fiscal year.
- Galera Therapeutics, Inc. reported Diluted EPS of $0.64 per share for fiscal year 2025.
- Galera Therapeutics, Inc. showed an increase of +288.2% in Diluted EPS compared to the prior fiscal year.
- Galera Therapeutics, Inc. reported Total Assets of $7.20 million for fiscal year 2025.
- Galera Therapeutics, Inc. showed a decrease of -28.8% in Total Assets compared to the prior fiscal year.
- Galera Therapeutics, Inc. reported Cash and Equivalents of $6.38 million for fiscal year 2025.
- Galera Therapeutics, Inc. showed a decrease of -23.1% in Cash and Equivalents compared to the prior fiscal year.
- Galera Therapeutics, Inc. reported Stockholders Equity of $3.97 million for fiscal year 2025.
- Galera Therapeutics, Inc. showed an increase of +102.7% in Stockholders Equity compared to the prior fiscal year.
- Galera Therapeutics, Inc. reported R&D Expense of $349.0 thousand for fiscal year 2025.
- Galera Therapeutics, Inc. showed a decrease of -88.9% in R&D Expense compared to the prior fiscal year.
- Galera Therapeutics, Inc. reported Operating Income of -$2.54 million for fiscal year 2025.
- Galera Therapeutics, Inc. showed an increase of +87.4% in Operating Income compared to the prior fiscal year.
- Galera Therapeutics, Inc. reported Shares Outstanding of 75.46 million shares for fiscal year 2025.
- Galera Therapeutics, Inc. showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: